Financial Shenanigans

Figures converted from INR at historical FX rates — see data/company.json.fx_rates. Ratios, margins, and multiples are unitless and unchanged.

Financial Shenanigans

Suzlon's forensic risk score is 52 / 100 (Elevated). The headline earnings story — record profits, debt-free balance sheet, 41% ROE — crumbles under cash-flow scrutiny. Two of the three highest-profit years in the last decade (FY23 and FY25) were dominated by non-cash items: a $33M debt-restructuring gain and a $16M cumulative deferred-tax-asset recognition. Three-year cash conversion of earnings is 0.30x — meaning 70 cents of every reported dollar of profit never showed up as operating cash. Meanwhile, trade receivables on the standalone balance sheet surged 230% in FY25 against 67% revenue growth, pushing debtor days from 72 to 130 in two years. The one thing that would upgrade this score: two consecutive quarters of CFO exceeding reported net income with stable debtor days.

---

Breeding Ground

The governance structure carries moderate risk for an Indian industrial with this history. The Tanti family controls the company operationally but owns only 11.7% of equity — the lowest promoter holding in the stock's history, and well below the 25%+ threshold that aligns founder incentives with minority shareholders. The reduction is not voluntary discipline; it is the mechanical result of a decade of dilutive equity raises (FY21 QIP, FY22 OCD-to-equity conversions, FY23 rights issue) needed to survive $200M+ of debt. In October 2025, the Tanti family sold 20 cr shares (~2.9% stake) via a block deal worth $15M — with a 180-day lock-in on further sales.

The breeding-ground risk is moderate. The company has genuinely been through near-death — CDR, SDR, S4A, ICA, Resolution Plan — which both explains the diluted promoter stake and creates a cultural tolerance for aggressive reporting (you don't survive six restructurings without learning to present numbers favorably). The FY25 restatement of FY24 standalone comparatives, noted by the auditor, is an open question: the scope and materiality of this restatement are not detailed in available data, which is itself a disclosure concern.

---

Earnings Quality

Suzlon's operating earnings are genuinely improving — but headline net profit in three of the last four reporting periods was materially inflated by non-cash items that do not represent ongoing earning power.

The non-cash distortion map:

FY23 net profit of $35M included $33M of "other income" — overwhelmingly the non-cash gain from converting $50M of OCDs to equity and writing off CCPS obligations under the 2020 resolution plan. Stripping this, FY23 operating net profit was roughly $1.8M. FY25 net profit of $24M included $7.5M from recognizing a deferred tax asset on carried-forward losses (PBT was only $16.9M). Adjusting for this, FY25 earnings were roughly $16.8M — still a strong improvement, but 31% below the headline.

In Q2 FY26, the same pattern repeated: PBT of $6.3M became net profit of $14.4M after an $8.1M DTA recognition. Cumulative DTA recognized across these two periods: $15.9M. This is legitimate accounting — the company has massive carried-forward tax losses from its FY14–FY20 losses — but the recognition is a management judgment call on future profitability, and each recognition is one-time.

Receivables vs revenue — the critical divergence:

Standalone trade receivables surged from $6.6M (FY23) to $43.1M (FY25) — a 553% increase over two years while revenue grew 75%. The standalone numbers are more useful than consolidated here because Suzlon's Indian WTG business is the core. Debtor days on a consolidated basis rose from 72 to 130 in the same window. For a WTG manufacturer where revenue recognition is milestone-based, this divergence signals one of three things: (a) customers are paying slower, (b) project milestones are being recognized before cash collection is certain, or (c) the mix has shifted toward longer-payment-cycle customers. All three reduce earnings quality even if revenue recognition is technically correct.

Margin trend — the clean signal:

Operating margins at 14–19% across 11 quarters are the cleanest signal in the P&L. These are not cosmetically inflated by one-time items — operating profit excludes the other income and tax items that distort the bottom line. The consistency supports the thesis that the core WTG business is genuinely profitable. The 200–300 bps quarterly swing is customer-mix driven, not an accounting artifact.

---

Cash Flow Quality

This is where the forensic case is strongest. Suzlon's operating cash flow has persistently and severely lagged reported net income, and the gap is not closing at the pace the revenue ramp suggests.

The 3-year CFO/NI of 0.30 is the single most damning number in this report. For every $1 of reported profit, Suzlon generated only $0.30 of operating cash. FY24 is the worst: $1.0M of CFO on $7.9M of net income. Even FY25, the "best operating year in a decade," converted only 53% of earnings to cash.

The mechanism: The gap comes from two sources. First, non-cash items inflating the denominator (debt restructuring gain in FY23, DTA in FY25). Second, working capital absorbing cash as the business scales.

Working capital — the cash sponge:

The cash conversion cycle at 145 days looks stable. But beneath this aggregate, the components are shifting in an unfavorable direction: DSO rising (72→130), DPO compressing from its FY24 high (165→156). The FY22–FY23 period was the cash-collection sweet spot; FY25 is a working-capital-intensive scaling phase. Standalone inventory more than doubled ($14M → $33M), consistent with building for a 6.4 GW order book — but this is cash out the door that hasn't yet returned.

The accrual ratio of 0.097 (FY25) confirms the pattern: net income significantly exceeds cash generation, and the gap is accumulating on the balance sheet as receivables and inventory.

---

Metric Hygiene

Suzlon reports under Indian GAAP (Ind AS) and does not heavily rely on non-GAAP or adjusted metrics. The primary investor-facing KPIs — order book (GW), quarterly deliveries (MW), and operating margin — are physically verifiable and consistently defined.

The most forensically relevant finding in metric hygiene is what Suzlon does not emphasize. The company highlights order book size, delivery records, and operating margins — all of which are genuinely strong. It does not prominently flag the 230% standalone receivable surge, the 12% FY24 cash conversion, or the fact that $15.9M of cumulative DTA recognition over two periods accounts for roughly a quarter of reported two-year profits. The headline P/E of 23.9x — cited widely and used by sell-side analysts — includes these DTA gains. On a normalized-tax basis (25% effective rate on PBT), FY25 EPS is closer to $0.009, and the adjusted P/E is roughly 72x. Using the numbers-claude estimate of adjusted EPS (which normalizes differently), the adjusted P/E is ~49x. Neither number resembles 23.9x.

---

What to Underwrite Next

Five items to track next quarter:

1. Standalone trade receivables — if the receivable-to-revenue growth gap persists (receivables growing faster than revenue for a third consecutive year), cash conversion cannot improve regardless of volume execution. The specific line: standalone trade receivables versus quarterly revenue, targeting DSO under 110 days.

2. Operating cash flow versus PBT — strip DTA and other income. The clean test is whether CFO exceeds PBT minus a 25% normal tax rate. FY25 failed this test (CFO $12.8M vs adjusted NP $12.7M — barely passing). FY24 failed badly (CFO $1.0M vs adjusted NP $5.9M).

3. DTA balance and remaining carried-forward losses — the $7.5M DTA recognized in FY25 and $8.1M in Q2 FY26 draw down a finite pool of accumulated losses. When the pool is exhausted, headline NP will step down sharply. Disclose: how much unrecognized DTA remains, and at what pace will it be recognized.

4. Renom acquisition working-capital impact — the $7.7M acquisition completing in tranches could contribute acquired receivables/payables that distort underlying cash trends. Monitor whether CFO improvement coincides with consolidation of Renom's balance sheet.

5. Contingent liabilities — standalone contingent liabilities surged from $2.1M (FY24) to $5.6M (FY25), a 174% increase. Composition and resolution trajectory are unknown from available data.

What would downgrade the forensic score to "High" (61+):

• A third consecutive year of receivables growing faster than revenue
• CFO/NI falling below 0.30 on a trailing-twelve-month basis
• Disclosure that DTA recognition assumptions are being revised upward (accelerated recognition)
• Auditor qualification or emphasis-of-matter paragraph on receivable collectibility

What would upgrade the score to "Watch" (21–40):

• Two consecutive quarters of CFO exceeding reported net income
• Debtor days stabilizing below 110
• Full disclosure of receivable aging with the greater-than-one-year bucket under $5.9M
• Clean audit opinion on FY26 standalone with no restatements

The bottom line for position sizing: The accounting risk here is a valuation haircut and position-sizing limiter, not a thesis breaker. The operating business is real — MW deliveries, operating margins, and the order book are verifiable and strong. But the headline earnings multiple is fiction: P/E of 23.9x should be read as 49–72x depending on normalization. An investor underwriting at the headline multiple is underwriting the wrong number. The correct approach is to value on operating cash flow or normalized PBT, apply a 15–25% haircut for receivable risk, and size the position knowing that the next two quarters of DTA-free earnings will look like a sharp "earnings miss" to anyone anchored to the $24M FY25 headline. The forensic risk is that the market hasn't priced the normalization yet.